Report Subject - Orphan Drugs - FirstWord Reports

Learn More Biosimilars: Go-to-Market Case Studies

As the biosimilar sector matures, what are the key issues that are shaping commercial strategies? As physician and payer confidence in the use of biosimilars grows, US and European companies are having to rethink their...

Compare
Learn More The Role of Patient Journey Mapping in Patient Engagement

Are you employing the latest technology and techniques to power your patient journey mapping? "Pharma companies first need to understand that their task is not to produce new product; their task is to provide a really...

Compare
Learn More Biomarkers and Companion diagnostics: Payer Insights

What do you need to do to get payer support for companion diagnostics and biomarkers? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand...

Compare
Learn More Trends in Investment by Big Pharma

What direction are big pharma investments taking? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why...

Compare
Learn More Orphan Drugs: The Importance of Real-World Evidence

Current expert thinking on how real-world evidence can refine orphan drug research, demonstrate stakeholder value and prove clinical effectiveness. Alarmed at the number of often highly-priced orphan drugs coming to...

Compare
Learn More Orphan Drug Commercial Models: Strategies for Success

Ensuring payer support, delivering stakeholder benefit and generating commercial returns: Pharma's growing orphan drug challenge Rising competition and closer scrutiny by hard-pressed payers are just two of the trends...

Compare
Learn More The ROI of Orphan Drugs: Ensuring Optimal Returns

Orphan drugs are at the forefront of medical science and offer a chance for the pharma industry to make a real difference to people's lives; there's also the lure of potentially lucrative commercial benefits for those...

Compare
Learn More Payer Attitudes to Orphan Drug Pricing

Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached...

Compare
Learn More Medical Affairs in Orphan Drugs

Orphan drugs: Is your medical affairs team leading the fray or lagging behind? Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...

Compare
Learn More Orphan Drugs: Pricing and Market Access Strategies

Orphan drug market access and pricing: strategies for success When it comes to securing market access and drug pricing for orphan drugs, a one size approach won’t work. Driven by increasing competition and cost...

Compare
Learn More The Future of Orphan Drugs

Orphan Drugs: Future opportunities and challenges The orphan drug sector is booming. Record product approvals, robust pipelines and regulatory incentives. But will the good times last? As the market matures...

Compare
Learn More Orphan Drug Market Access: Payer Insights on the Present and Future (2016)

How to ensure positive payer engagement for orphan drug market access The explosion in orphan drug approvals and high prices are causing increasing concern to payers. When there were few orphan drugs for small patient...

Compare
Learn More Orphan Drug Commercial Models: Sustaining the rare disease business

Choosing the right commercial model for orphan drug success The societal and commercial ambitions of orphan drug developers determine which commercial model will best meet their aims. Profit, potential and patient...

Compare
Learn More Patient Engagement in Orphan Drugs

Why is the patient voice critical to orphan drug success? Patient input is critical to an orphan drug’s success, but how and when should you engage and what trends and drivers are shaping their involvement?...

Compare
Learn More Commercial Excellence in Rare Diseases and Orphan Drugs

Developing therapies for orphan diseases is attracting much industry interest with the promise of profits. But what are the specific R&D, regulatory, stakeholder and market access issues you need to understand and...

Compare

Browse by